Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study.
Saved in:
| Title: | Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study. |
|---|---|
| Authors: | Bahlis NJ; Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Canada., Zonder J; Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA., Karlin L; Department of Hematology, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France., Plesner T; Vejle Hospital, University of Southern Denmark, Vejle, Denmark., Paris L; Division of Hematology, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy., Wrobel T; Uniwersytet Medyczny we Wrocławiu, Wroclaw, Poland., Hungria V; Clínica Medica São Germano, São Paulo, Brazil., Besemer B; Abteilung für Innere Medizin II, Universitätsklinikum Tübingen der Eberhard-Karls-Universität, Tübingen, Germany., Crusoe E; Hospital São Rafael, Instituto D'Or de Pesquisa e Ensino and Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia-HUPES-UFBA, Salvador, Brazil., Silkjaer T; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark., Perrot A; Université de Toulouse, CHU de Toulouse, Service d'Hématologie, Toulouse, France., Moreau P; Hematology Department, University Hospital Hôtel-Dieu, Nantes, France., Wu KL; ZNA Stuivenberg, Antwerp, Belgium., Delimpasi S; Evangelismos Hospital, Athens, Greece., Dimopoulos MA; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.; Department of Medicine, Korea University, Seoul, South Korea., Levin MD; Albert Schweitzer Hospital, Dordrecht, The Netherlands., Mangiacavalli S; Division of Hematology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy., Nnane I; Johnson & Johnson, Washington, PA, USA., Kim YJ; Johnson & Johnson, Raritan, NJ, USA., Krevvata M; Johnson & Johnson, Washington, PA, USA., Sha L; Johnson & Johnson, Shanghai, China., Wroblewski S; Johnson & Johnson, Washington, PA, USA., Tuozzo A; Johnson & Johnson, Washington, PA, USA., Carson R; Johnson & Johnson, Washington, PA, USA., Facon T; University of Lille, CHU Lille, Lille, France. |
| Source: | Leukemia & lymphoma [Leuk Lymphoma] 2025 Dec; Vol. 66 (14), pp. 2685-2696. Date of Electronic Publication: 2025 Oct 03. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Multicenter Study |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1029-2403 |
|---|---|
| DOI: | 10.1080/10428194.2025.2561117 |
